Holen Sie sich die Stockscreener-App
108.28
0.06%
0.06
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$108.22
Offen:
$108.38
24-Stunden-Volumen:
3.57M
Relative Volume:
0.44
Marktkapitalisierung:
$134.69B
Einnahmen:
$28.73B
Nettoeinkommen (Verlust:
$5.97B
KGV:
22.80
EPS:
4.75
Netto-Cashflow:
$9.84B
1W Leistung:
-3.40%
1M Leistung:
-0.20%
6M Leistung:
+16.48%
1J Leistung:
+49.23%
1-Tages-Spanne:
$107.75
$109.38
1-Wochen-Bereich:
$107.75
$111.49
52-Wochen-Spanne:
$70.78
$119.96
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
108.28 | 139.43B | 28.73B | 5.97B | 9.84B | 4.75 |
|
LLY
Lilly Eli Co
|
762.18 | 717.60B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
164.36 | 377.32B | 90.63B | 22.66B | 18.57B | 9.35 |
|
ABBV
Abbvie Inc
|
184.85 | 338.30B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
114.14 | 234.32B | 55.19B | 13.65B | 16.81B | 6.86 |
|
NVO
Novo Nordisk Adr
|
64.92 | 306.33B | 43.59B | 15.04B | 10.74B | 3.3766 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
After Gilead Deal, Hookipa Hangs Up Its Hat - insights.citeline.com
Gilead Sciences Inc. Stock Analysis and ForecastMarket-leading growth rates - jammulinksnews.com
What drives Gilead Sciences Inc. stock priceExtraordinary market timing - Autocar Professional
Gilead’s HIV Strength Drives Gains, But Pipeline Is Key - Finimize
Why Gilead Sciences (GILD) Appeals to Income Investors in the Pharma Sector - MSN
Is Gilead Sciences Inc. a good long term investmentFree Wealth Planning Blueprint - Jammu Links News
Lobbying Update: $90,000 of GILEAD SCIENCES INC. lobbying was just disclosed - Quiver Quantitative
What analysts say about Gilead Sciences Inc. stockRapid wealth multiplication - jammulinksnews.com
HOOKIPA Pharma Inc. Announces Intent to Voluntarily Delist from Nasdaq and Pursue Asset Sale with Gilead Sciences - Quiver Quantitative
HOOKIPA Pharma Exits Nasdaq Market as Gilead Sciences Acquires Key Drug Programs - Stock Titan
Foster City drugs giant Gilead to pay $202 million over alleged kickback scheme - SiliconValley.com
Pennsylvania to receive $1.2M from Gilead over kickback scheme to promote HIV drugs - WPXI
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc.GILD - PR Newswire
Attorney General Ellison helps secure $200M from Gilead for paying illegal kickbacks - Red Lake Nation News
Gilead Sciences Inc. Agrees to $202 Million Settlement Over Kickbacks, Illinois Leads Charge with Multi-State Coalition - Hoodline
Gilead To Pay $202 Million In Nationwide Settlement Over Illegal HIV Drug Kickback Scheme - MyChesCo
Gilead Sciences CFO Dickinson sells $277k in stock By Investing.com - Investing.com South Africa
Gilead reaches $202M settlement over kickback scheme to promote HIV drug - Crain's New York Business
Troy Griffin on Gilead’s mission at Chosen Few picnic - rollingout.com
Why Merck Is A Better Dividend Stock Than Gilead Sciences (NYSE:MRK) - Seeking Alpha
Nevada to receive over $440K from Gilead settlement over alleged illegal kickbacks - KTVN
Gilead Sciences Advances in Triple-Negative Breast Cancer Treatment - TipRanks
Minnesota and Iowa join $202M Gilead settlement over kickbacks - KIMT
New York AG Letitia James Clinches Monumental $202M Victory Against Gilead Sciences Over HIV Med Kickbacks - Hoodline
Attorney General Raoul Announces More Than $200 Million Settlement With Gilead Sciences Over Illegal Kickbacks To Providers For Prescriptions - RiverBender.com
Pennsylvania to Receive Over $1.2 Million in HIV Drug Kickback Settlement with Gilead - Franklin County Free Press
AG Sunday Part of National Coalition Securing $200M+ from Gilead Sciences for Illegal Kickback Scheme to Sell HIV Drugs - exploreJefferson
GILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law Firm - WV News
Gilead’s Vítor Papão on key partnerships and the role of tech in public health - Gulf Business
Attorney General Bonta Helps Secure Over $200 Million from Gilead Sciences for Paying Illegal KickbacksState of California - State of California - Department of Justice (.gov)
Here's Why Gilead Sciences (GILD) Fell More Than Broader Market - Yahoo Finance
Tamar Braxton partners with Gilead for HIV awareness - Rolling Out
Sector Update: Health Care - MarketScreener
Pennsylvania to receive $1.28 million in settlement over Gilead’s illegal HIV drug kickback scheme - WTAJ
Tamar Braxton & Gilead Partner For PrEP Promo To Black Women - Black America Web
Gilead Sciences Reaches $202 Million Settlement Over Kickback Scheme Promoting HIV Drugs - MarketScreener
Pennsylvania Part of National Coalition Securing $200M+ from Gilead Sciences for Illegal Kickback Scheme to Sell HIV Drugs - pennwatch.org
Pennsylvania expected to get $1.28 million from biopharma company for violating anti-kickback laws - ABC27
Massachusetts Secures $1.6 Million from Gilead in $202 Million Multi-State Settlement Over HIV Drug Kickbacks - Hoodline
Gilead reaches $202M settlement over HIV drug speaker program - Seeking Alpha
Tamar Braxton Partners with Gilead to Empower Black Women on HIV Prevention - ThisisRnB.com
Bernstein Maintains Buy Rating on Gilead Sciences (GILD) Stock - Insider Monkey
Gilead Beats Defamation Suit by Worker Accused of Sex Harassment - Bloomberg Law News
Fighting Disease Requires More Than Just the Right Drug: Gilead - Mexico Business News
Gilead Sciences (GILD) Reaches Deal to Offer HIV Vaccine to Low and Middle-Income Nations - MSN
Gilead, GSK/ViiV, Merck Present New HIV PrEP Frontiers at IAS25 - BioSpace
Attorney General Schwalb Recovers Over $300,000 from Gilead Sciences for Illegal Kickback Scheme - District of Columbia | Attorney General (.gov)
How the Inhaled Antibiotics Market Will Evolve by 2032Growth, - openPR.com
Gilead's twice-yearly HIV PrEP set for wider rollout - pharmaphorum
Gilead’s twice-yearly HIV prevention shot effective across diverse groups By Investing.com - Investing.com Nigeria
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):